CN100490826C - Method for preparing concatenated active bifidobacterium product - Google Patents
Method for preparing concatenated active bifidobacterium product Download PDFInfo
- Publication number
- CN100490826C CN100490826C CNB2005100355847A CN200510035584A CN100490826C CN 100490826 C CN100490826 C CN 100490826C CN B2005100355847 A CNB2005100355847 A CN B2005100355847A CN 200510035584 A CN200510035584 A CN 200510035584A CN 100490826 C CN100490826 C CN 100490826C
- Authority
- CN
- China
- Prior art keywords
- bifidobacterium
- dry powder
- cfu
- bifidobacteria
- product
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 241000186000 Bifidobacterium Species 0.000 title claims abstract description 30
- 239000000843 powder Substances 0.000 claims abstract description 28
- 238000002360 preparation method Methods 0.000 claims abstract description 8
- 241000894006 Bacteria Species 0.000 claims description 15
- 241000186012 Bifidobacterium breve Species 0.000 claims description 7
- 241001608472 Bifidobacterium longum Species 0.000 claims description 7
- 229940009291 bifidobacterium longum Drugs 0.000 claims description 7
- 241000186660 Lactobacillus Species 0.000 claims description 6
- 229940039696 lactobacillus Drugs 0.000 claims description 6
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims description 3
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 3
- 229920002774 Maltodextrin Polymers 0.000 claims description 3
- 239000005913 Maltodextrin Substances 0.000 claims description 3
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 claims description 3
- 239000004473 Threonine Substances 0.000 claims description 3
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims description 3
- 235000004279 alanine Nutrition 0.000 claims description 3
- 230000003749 cleanliness Effects 0.000 claims description 3
- 230000007613 environmental effect Effects 0.000 claims description 3
- 239000008101 lactose Substances 0.000 claims description 3
- 229940035034 maltodextrin Drugs 0.000 claims description 3
- 235000013336 milk Nutrition 0.000 claims description 3
- 239000008267 milk Substances 0.000 claims description 3
- 210000004080 milk Anatomy 0.000 claims description 3
- 239000004474 valine Substances 0.000 claims description 3
- 229930003270 Vitamin B Natural products 0.000 claims description 2
- 235000019156 vitamin B Nutrition 0.000 claims description 2
- 239000011720 vitamin B Substances 0.000 claims description 2
- 150000001413 amino acids Chemical class 0.000 abstract description 2
- 229920001542 oligosaccharide Polymers 0.000 abstract description 2
- 150000002482 oligosaccharides Chemical class 0.000 abstract description 2
- 230000001580 bacterial effect Effects 0.000 abstract 3
- 230000001737 promoting effect Effects 0.000 abstract 1
- 241000186016 Bifidobacterium bifidum Species 0.000 description 5
- 241000186018 Bifidobacterium adolescentis Species 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 229940002008 bifidobacterium bifidum Drugs 0.000 description 2
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 241000186015 Bifidobacterium longum subsp. infantis Species 0.000 description 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 1
- 241000194020 Streptococcus thermophilus Species 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 238000009455 aseptic packaging Methods 0.000 description 1
- 229940004120 bifidobacterium infantis Drugs 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 244000005706 microflora Species 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Landscapes
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The present invention relates to a preparation method of multiple active bifidobacterium products. It is characterized by that according to the requirements of different crowds said invention adopts different kinds of bifidobacterium live bacterial powders to preparae multiple bifidobacterium live bacterial dried powders. In these multiple bifidobacterium live bacterial dried powders the oligosaccharides with the function of promoting multiplication and amino acids can be added so as to obtain the invented multiple active bifidobacterium products.
Description
Technical field
The present invention relates to the preparation method of the preparation method of a kind of physiological antibacterial, particularly a kind of concatenated active bifidobacterium.
Background technology
Bacillus bifidus is and the extremely close a kind of normal physiological antibacterial of human health relation, but along with the pollution and the antibiotic abuse of environment, makes this micro-flora content of normal human reduce greatly, has a strong impact on the healthy of people.In order to bring benefit to the people, development can be grown the storage at normal temperature phase, bifidobacteria viable bacteria is counted height and the strong bacillus bifidus product of stomach juice-resistant just seems particularly needs.
Through years of researches and exploration, we utilize brand-new fermentation technology to turn out different types of bacillus bifidus, and, comprise bifidobacteria infantis (Bifidobacterium infantis), bifidobacterium breve (Bifidobacterium breve), bifidobacterium bifidum (Bifidobacteriumbifidum), bifidobacterium adolescentis (Bifidobacterium adolescentis), bifidobacterium longum (Bifidobacterium longum), lactobacillus (L bulgaricus), streptococcus thermophilus (Sthermophilus) etc. through freeze dried viable bacteria powder.
Summary of the invention
Be prepared into multi-joint bifidobacteria viable bacteria dry powder according to different human needs with different types of bifidobacteria viable bacteria powder, in these multi-joint bifidobacteria viable bacteria dry powder, add the oligosaccharides that promotes such flora propagation simultaneously, and the concatenated active bifidobacterium product that the significant materials such as aminoacid of human body is consisted of the present invention.
The present invention's prescription by:
Multi-joint bifidobacteria viable bacteria dry powder X%
Defatted milk powder 30%
Oligofructose 10%
Lactose 40-X%
Maltodextrin 15%
Alanine 1.5%
Valine 1.5%
Threonine 1.5%
Vitamin B
20.5% forms product index: viable count 〉=1.0 * 10
6Cfu/g,
Must in being 100 grades environmental condition, operate cleanliness factor during preparation.
Product of the present invention has long, bifidobacteria viable bacteria of storage at normal temperature phase and counts advantages such as height and stomach juice-resistant are strong.
The specific embodiment
Describe in detail below in conjunction with embodiment.
Example:
Preparation 1000g concatenated active bifidobacterium product, viable count is 1.0 * 10
8Cfu/g, and form by bifidobacterium breve, bifidobacteria infantis, bifidobacterium longum and lactobacillus tetrad bacterium, containing the bacterium ratio is 1:1:1:1 substantially.
Setting bifidobacterium breve dry powder viable count is 2.3 * 10
9Cfu/g, bifidobacteria infantis dry powder viable count is 1.3 * 10
9Cfu/g, bifidobacterium longum dry powder viable count is 2.03 * 10
12Cfu/g, lactobacillus dry powder viable count is 1.63 * 10
8Cfu/g.
According to formula for a product, be to take by weighing respectively in 100 grades the environmental condition and after sterilization at cleanliness factor:
Bifidobacterium breve dry powder: 1.0 * 10
8÷ 4 ÷ (2.3 * 10
9) * 1000=10.9g
Bifidobacteria infantis dry powder: 1.0 * 10
8÷ 4 ÷ (1.3 * 10
9) * 1000=19.2g
Bifidobacterium longum dry powder: 1.0 * 10
8÷ 4 ÷ (2.03 * 10
12) * 1000=0.02g
Lactobacillus dry powder: 1.0 * 10
8÷ 4 ÷ (1.63 * 10
8) * 1000=24.3g
Be that multi-joint bifidobacteria dry powder is: 10.9g+19.2g+0.02g+24.3g=54.42g; Therefore:
Multi-joint bifidobacteria viable bacteria dry powder X=54.42 ÷ 1000 * 100=5.44, so,
Lactose: (40-5.44) % * 1000=345.6g;
Defatted milk powder: 30% * 1000=300g;
Oligofructose: 10% * 1000=100g;
Maltodextrin: 15% * 1000=150g;
Alanine, valine, threonine respectively are: 1.5% * 1000=15g;
Vitamin B
2: 0.5% * 1000=5g.
With the material mix homogeneously of above-mentioned prescription, aseptic packaging promptly gets the 1000g concatenated active bifidobacterium product.
Claims (2)
1, a kind of preparation method of concatenated active bifidobacterium product is characterized in that: this formula for a product by
Multi-joint bifidobacteria viable bacteria dry powder X%
Defatted milk powder 30%
Oligofructose 10%
Lactose 40-X%
Maltodextrin 15%
Alanine 1.5%
Valine 1.5%
Threonine 1.5%
Vitamin B
10.5% forms, in the prescription〉0;
Multi-joint bifidobacteria viable bacteria dry powder is made up of freeze dried bifidobacterium breve, bifidobacteria infantis, bifidobacterium longum and lactobacillus tetrad bacterium in the prescription, and containing the bacterium ratio is 1:1:1:1;
Setting bifidobacterium breve dry powder viable count in the multi-joint bifidobacteria viable bacteria dry powder is 2.3 * 10
9Cfu/g, bifidobacteria infantis dry powder viable count is 1.3 * 10
9Cfu/g, bifidobacterium longum dry powder viable count is 2.03 * 10
12Cfu/g, lactobacillus dry powder viable count is 1.63 * 10
8Cfu/g.
2, a kind of preparation method according to claim 1 is characterized in that: must operate in cleanliness factor is 100 grades environmental condition when concatenated active bifidobacterium product prepares, viable count is 1.0 * 10
8Cfu/g.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2005100355847A CN100490826C (en) | 2005-07-05 | 2005-07-05 | Method for preparing concatenated active bifidobacterium product |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2005100355847A CN100490826C (en) | 2005-07-05 | 2005-07-05 | Method for preparing concatenated active bifidobacterium product |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1891236A CN1891236A (en) | 2007-01-10 |
| CN100490826C true CN100490826C (en) | 2009-05-27 |
Family
ID=37596596
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB2005100355847A Active CN100490826C (en) | 2005-07-05 | 2005-07-05 | Method for preparing concatenated active bifidobacterium product |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN100490826C (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL2481299T3 (en) * | 2011-01-31 | 2017-09-29 | Synformulas Gmbh | Bifidobacterium bifidum strains for application in gastrointestinal diseases |
| CN108741084A (en) * | 2018-05-18 | 2018-11-06 | 珠海中食月太健康科技有限公司 | A kind of product improving enteron aisle defaecation |
-
2005
- 2005-07-05 CN CNB2005100355847A patent/CN100490826C/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN1891236A (en) | 2007-01-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Fooks et al. | Probiotics as modulators of the gut flora | |
| TW579279B (en) | Food or drink product with a disinfection property of helicobacter pylori | |
| US9579353B2 (en) | Pharmaceutical compositions containing pediococcus and methods for reducing the symptoms of gastroenterological syndromes | |
| Popova et al. | Beneficial effects of probiotics in upper respiratory tract infections and their mechanical actions to antagonize pathogens | |
| CA2436752C (en) | Bifidobacteria and preparations containing them | |
| US20200121740A1 (en) | Pharmaceutical compositions containing pediococcus and methods for reducing the symptoms of gastroenterological syndromes | |
| Gul | Microencapsulation of Lactobacillus casei Shirota by spray drying using different combinations of wall materials and application for probiotic dairy dessert | |
| CN107136279A (en) | A kind of lactic acid bacteria pressed candy and preparation method thereof | |
| Bruno et al. | Viability of two freeze‐dried strains of Bifidobacterium and of commercial preparations at various temperatures during prolonged storage | |
| JP2008509131A (en) | Folic acid producing Bifidobacterium strains, preparations and uses thereof | |
| CA2333205A1 (en) | A beneficial microbe composition, new protective materials for the microbes, the method to prepare and uses thereof | |
| CA2434337A1 (en) | Combination of probiotics | |
| JP2002537865A5 (en) | ||
| CN102132883A (en) | Probiotic bacterium food supplement, and preparation method and use thereof | |
| CA2380849A1 (en) | New bifidobacteria preventing diarrhea caused by pathogenic bacteria | |
| López-Huertas | Safety and efficacy of human breast milk Lactobacillus fermentum CECT 5716. A mini-review of studies with infant formulae | |
| CN100497594C (en) | Composite protector for high activity bifidobacteria dry powder formulation | |
| Jayalalitha et al. | In vitro assessment of microencapsulated probiotic beads. | |
| CN100490826C (en) | Method for preparing concatenated active bifidobacterium product | |
| Vijaya Kumar et al. | Beneficial effects of probiotics and prebiotics on human health | |
| ITMI20070452A1 (en) | COMPRESSOR INCLUDING MICRO-ORGANISMS AND A COMBINATION OF EXCIPIENTS AND RELATIVE PRODUCTION PROCEDURE | |
| CA2378426A1 (en) | Bifidobacteria capable of preventing diarrhea | |
| Agrawal et al. | Role of'live microorganisms'(probiotics) in prevention of caries: Going on the natural way towards oral health | |
| CN102406667A (en) | Probiotic oral administration preparation for preventing neonate antibiotic-associated diarrhea and technology | |
| ITMI20100081A1 (en) | STRETCH OF LACTOBACILLUS PARACASEI PC201, ITS COMPOSITIONS AND ITS USES |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| EE01 | Entry into force of recordation of patent licensing contract |
Application publication date: 20070110 Assignee: SHANDONG XIANPU AIRUI TECHNOLOGY Co.,Ltd. Assignor: GUANGDONG INSTITUTE OF MICROBIOLOGY Contract record no.: 2015370000012 Denomination of invention: Method for preparing concatenated active bifidobacterium product Granted publication date: 20090527 License type: Exclusive License Record date: 20150202 |
|
| EC01 | Cancellation of recordation of patent licensing contract |
Assignee: SHANDONG XIANPU AIRUI TECHNOLOGY Co.,Ltd. Assignor: GUANGDONG INSTITUTE OF MICROBIOLOGY Contract record no.: 2015370000012 Date of cancellation: 20160713 |
|
| LICC | Enforcement, change and cancellation of record of contracts on the licence for exploitation of a patent or utility model | ||
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20200930 Address after: 510663 1 steeple Hill Road, Guangzhou, Guangdong, Luogang District Patentee after: Guangzhou Institute of Microbiology Co.,Ltd. Address before: 510250 Guangdong city of Guangzhou province Haizhuqu District Baogang Avenue Lai Fuk Road No. 68 Patentee before: GUANGDONG INSTITUTE OF MICROBIOLOGY |
|
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20220802 Address after: Room 503, building 6, No. 1, jiantashan Road, Huangpu District, Guangzhou, Guangdong 510663 Patentee after: Guangzhou gaoxinguang Microbial Technology Co.,Ltd. Address before: 510663 1 Pinnacle Road, Luogang District, Guangzhou, Guangdong Patentee before: Guangzhou Institute of Microbiology Co.,Ltd. |